Drug Profile


Alternative Names: VT-464

Latest Information Update: 19 Dec 2016

Price : $50

At a glance

  • Originator Viamet Pharmaceuticals
  • Developer Innocrin Pharmaceuticals; Viamet Pharmaceuticals
  • Class Antiandrogens; Antineoplastics; Fluorine compounds; Naphthalenes; Propanols; Small molecules; Triazoles
  • Mechanism of Action Androgen receptor antagonists; Estrogen receptor antagonists; Steroid 17-alpha-hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Prostate cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Breast cancer; Prostate cancer

Most Recent Events

  • 13 Dec 2016 Efficacy, adverse events and pharmacodynamics data from a phase II trial in Breast cancer presented at the 39th annual San Antonio Breast Cancer Symposium (SABCS-2016)
  • 06 Oct 2016 Phase-II clinical trials in Breast cancer (Late stage disease) in USA (PO) (NCT02580448)
  • 06 Jan 2016 VT 464 receives Fast Track designation for Prostate cancer [PO,Capsule] (Late-stage disease, Second-line therapy or greater, Metastatic disease) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top